Vectra 3D

dinotefuran, permethrin, and pyriproxyfen

Opinion

On 21 March 2019, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion, recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Vectra 3D. The marketing authorisation holder for this veterinary medicinal product is CEVA Santé Animale.

Vectra 3D is currently authorised in dogs as spot-on solution for the treatment and prevention of flea, tick, sand fly, mosquito and stable fly infestations. The variation concerns the change of legal status from prescription-only to non-prescription veterinary medicine.

Detailed conditions for the use of this product are described in the updated summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the revised European public assessment report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

Key facts

Name
Vectra 3D
Agency product number
EMEA/V/C/002555
International non-proprietary name (INN) or common name
  • dinotefuran, permethrin, and pyriproxyfen
Species
Dogs
Active substance
  • dinotefuran, permethrin, and pyriproxyfen
Date opinion adopted
21/03/2019
Company name
Ceva Sante Animale
Status
Positive
Application type
Post-authorisation

Related content

How useful was this page?

Add your rating